Boston Scientific has lost more than half its value in eleven months, and almost every explanation you will read blames a slowdown. That is true but imprecise, and the imprecision is where the opportunity or the trap sits. The company’s June-quarter results were not weak: net sales rose 7.5% to $5.442bn, gross margin expanded 305
Fading Fed rate-hike odds, expired Hormuz diplomacy, and joint US-Japan currency interventions have driven down the US Dollar.. Collapse in September Rate-Hike Odds Drives DXY Below 200-Day EMA Expectations for monetary tightening by the United States central bank have cooled rapidly following a sequence of softer domestic economic reports. Disappointing figures—including a monthly contraction in
EURJPY currency pair can be expected to rise further to the next resistance level 185.30 – former support from the middle of July. EURJPY broke resistance zone Likely to rise to resistance level 185.30 EURJPY currency pair recently broke the resistance zone lying at the intersection of the resistance level 184.00 (former support which has
AST SpaceMobile has spent four years being valued on a single question: can it raise enough money to finish the constellation? As of last month, that question is answered. After a $1.15 billion convertible offering, management reported pro forma cash and liquidity of over $3.7 billion — against a remaining build that, on the company’s
For twenty years, the single most reliable fact about Alphabet was that it printed cash and handed a large slice of it back. In 2025 it repurchased $45.7 billion of its own stock. In the first half of 2026 it repurchased zero — and instead sold $30.5 billion of common stock, $19.1 billion of mandatory
IonQ did not lose $1.9 billion last quarter. It earned record revenue, raised guidance, closed a $1.8 billion acquisition — and then booked a $1.6 billion non-cash charge because its own share price went up. That single accounting mechanic is the most misunderstood thing about IonQ (NYSE: IONQ) right now, and it explains why the